



UNIL | Université de Lausanne

Unicentre  
CH-1015 Lausanne  
<http://serval.unil.ch>

---

Year : 2020

## Development and Multi-Cohort Validation of a Clinical Score for Predicting Type 2 Diabetes Mellitus

Kraege Vanessa

Kraege Vanessa, 2020, Development and Multi-Cohort Validation of a Clinical Score for Predicting Type 2 Diabetes Mellitus

Originally published at : Thesis, University of Lausanne

Posted at the University of Lausanne Open Archive <http://serval.unil.ch>  
Document URN : urn:nbn:ch:serval-BIB\_517CDC8268830

### **Droits d'auteur**

L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir le consentement préalable de l'auteur et/ou de l'éditeur avant toute utilisation d'une oeuvre ou d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière.

### **Copyright**

The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose offenders to the sanctions laid down by this law. We accept no liability in this respect.



UNIL | Université de Lausanne

Faculté de biologie  
et de médecine

---

**UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE**

Département de médecine

Service de médecine interne

---

**Development and Multi-Cohort Validation of a Clinical Score for Predicting  
Type 2 Diabetes Mellitus**

THESE

préparée sous la direction du Professeur Peter Vollenweider  
avec la co-direction de Docteure Marie Méan  
avec la collaboration du Professeur Pedro Marques-Vidal  
et du Professeur Gérard Waeber

et présentée à la Faculté de biologie et de médecine de  
l'Université de Lausanne pour l'obtention du grade de

DOCTEUR EN MEDECINE

par

Vanessa KRAEGE

Médecin diplômée de la Confédération Suisse  
Originaire de Saint-Sulpice (Vaud/Suisse)

Lausanne  
2020

# Imprimatur

*Vu le rapport présenté par le jury d'examen, composé de*

**Directeur de thèse**      *Monsieur le Professeur **Peter Vollenweider***

**Co-Directeur de thèse**      *Madame la Docteure **Marie MEAN***

**Expert**      *Madame la Professeure **Jardena Puder***

**Vice-Directeur de  
l'Ecole doctorale**      *Monsieur le Professeur **John Prior***

*la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de*


**Madame Vanessa KRAEGE**

*intitulée*

**Development and Multi-Cohort Validation of a Clinical Score for  
Predicting Type 2 Diabetes Mellitus**

*Lausanne, le 6 février 2020*

*pour Le Doyen  
de la Faculté de Biologie et de Médecine*



*Monsieur le Professeur John Prior  
Vice-Directeur de l'Ecole doctorale*

## Résumé

### Contexte et buts

Nombreux sont les pays n'ayant pas les moyens d'identifier les patients à risque de développer un diabète de type 2. Notre but était de développer et valider un score de risque de diabète, basé sur des variables cliniques facilement accessibles.

### Méthodes

Etude prospective incluant 5277 participants (55.0% femmes, âge  $51.8 \pm 10.5$  années) sans diabète au départ. Comparaison avec 2 autres scores de diabète existants (Balkau et Kahn clinique, respectivement 5 et 8 variables) et validation sur trois cohortes (Europe, Iran et Mexique).

### Résultats

Après un suivi moyen de 10.9 ans, 405 participants (7.7%) avaient développé un diabète. Notre score était basé sur l'âge, le sexe, le tour de taille, les antécédents familiaux de diabète, l'hypertension et l'activité physique. L'aire sous la courbe (AUC) était de 0.772 pour notre score, vs. 0.748 ( $p < 0.001$ ) et 0.774 ( $p = 0.668$ ) pour les deux autres. Avec un seuil à 13 points, la sensibilité, spécificité, valeur prédictive positive et négative (95% CI) de notre score étaient respectivement 60.5 (55.5-65.3), 77.1 (75.8-78.2), 18.0 (16.0-20.1) et 95.9 (95.2-96.5) pourcent. Notre score se comportait aussi bien ou mieux que les deux autres dans les cohortes iranienne [AUC 0.542 vs. 0.564 ( $p = 0.476$ ) et 0.513 ( $p = 0.300$ )] et mexicaine [AUC 0.791 vs. 0.672 ( $p < 0.001$ ) et 0.778 ( $p = 0.575$ )]. Dans la cohorte européenne, il se comportait de façon similaire au score de Balkau mais moins bien que le Kahn clinique [AUC 0.788 vs. 0.793 ( $p = 0.091$ ) et 0.816 ( $p < 0.001$ )]. La capacité diagnostique de notre score était meilleure que celle de Balkau et comparable à celle de Kahn clinique.

### Conclusion

Notre score clinique montre des résultats encourageants par rapport à d'autres scores et peut être utilisé dans des populations à prévalences différentes de diabète.

## RESEARCH ARTICLE

## Development and multi-cohort validation of a clinical score for predicting type 2 diabetes mellitus

Vanessa Kraege<sup>1\*</sup>, Peter Vollenweider<sup>1</sup>, Gérard Waeber<sup>1</sup>, Stephen J. Sharp<sup>2</sup>, Maite Vallejo<sup>3</sup>, Oscar Infante<sup>3</sup>, Mohammad Reza Mirjalili<sup>4</sup>, Fatemeh Ezoddini-Ardakani<sup>4</sup>, Hassan Mozaffari-Khosravi<sup>4</sup>, Mohammad Hasan Lotfi<sup>4</sup>, Masoud Mirzaei<sup>4</sup>, Marie Méan<sup>1</sup>, Pedro Marques-Vidal<sup>1</sup>

**1** Department of Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland, **2** MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, England, United Kingdom, **3** Tlalpan 2020 Study, Department of Socio-Medical Research, National Institute of Cardiology, Ignacio Chávez, Mexico City, Mexico, **4** Shahid Sadoughi University of Medical Sciences, Yazd, Iran

☞ These authors contributed equally to this work.

\* [vanessa.kraege@chuv.ch](mailto:vanessa.kraege@chuv.ch)



## OPEN ACCESS

**Citation:** Kraege V, Vollenweider P, Waeber G, Sharp SJ, Vallejo M, Infante O, et al. (2019) Development and multi-cohort validation of a clinical score for predicting type 2 diabetes mellitus. *PLoS ONE* 14(10): e0218933. <https://doi.org/10.1371/journal.pone.0218933>

**Editor:** Cheng Hu, Shanghai Diabetes Institute, CHINA

**Received:** February 24, 2019

**Accepted:** June 12, 2019

**Published:** October 9, 2019

**Copyright:** © 2019 Kraege et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The study participants have not provided consent to publicly share the individual level data underlying this study. Information related to data access is available to qualified, interested researchers at <https://www.colaus-psycolaus.ch/professionals/how-to-collaborate/>. All responses to data sharing requests must comply with the ethical and legal constraints of Switzerland.

**Funding:** The CoLaus/PsyCoLaus study was and is supported by research grants from

## Abstract

## Background and aims

Many countries lack resources to identify patients at risk of developing Type 2 diabetes mellitus (diabetes). We aimed to develop and validate a diabetes risk score based on easily accessible clinical data.

## Methods

Prospective study including 5277 participants (55.0% women, 51.8±10.5 years) free of diabetes at baseline. Comparison with two other published diabetes risk scores (Balkau and Kahn clinical, respectively 5 and 8 variables) and validation on three cohorts (Europe, Iran and Mexico) was performed.

## Results

After a mean follow-up of 10.9 years, 405 participants (7.7%) developed diabetes. Our score was based on age, gender, waist circumference, diabetes family history, hypertension and physical activity. The area under the curve (AUC) was 0.772 for our score, vs. 0.748 ( $p < 0.001$ ) and 0.774 ( $p = 0.668$ ) for the other two. Using a 13-point threshold, sensitivity, specificity, positive and negative predictive values (95% CI) of our score were 60.5 (55.5–65.3), 77.1 (75.8–78.2), 18.0 (16.0–20.1) and 95.9 (95.2–96.5) percent, respectively. Our score performed equally well or better than the other two in the Iranian [AUC 0.542 vs. 0.564 ( $p = 0.476$ ) and 0.513 ( $p = 0.300$ )] and Mexican [AUC 0.791 vs. 0.672 ( $p < 0.001$ ) and 0.778 ( $p = 0.575$ )] cohorts. In the European cohort, it performed similarly to the Balkau score but worse than the Kahn clinical [AUC 0.788 vs. 0.793 ( $p = 0.091$ ) and 0.816 ( $p < 0.001$ )].

GlaxoSmithKline (<https://www.gsk.com/>), the Faculty of Biology and Medicine of Lausanne (<http://unil.ch/fbm/home.html>), and the Swiss National Science Foundation ([www.snf.ch](http://www.snf.ch), grants 33CS30-122661, 33CS30-139468, 33CS30-148401). Gérard Waeber is supported by the Swiss National Science Foundation grant 32003B 173092. Incident diabetes cases in the European cohort were ascertained and verified as part of the EPIC-InterAct project, which was funded by the EU FP6 programme ([https://cordis.europa.eu/guidance/archive\\_en.html](https://cordis.europa.eu/guidance/archive_en.html), grant number LSHM\_CT\_2006\_037197). Tlalpan 2020 is funded by the National Council for Science and Technology (Consejo Nacional de Ciencia y Tecnología – CONACYT - <https://www.conacyt.gob.mx/>) under the ‘Cátedras CONACYT’ program, No 1591. Funding was also received from AstraZeneca Mexico (<https://www.astrazeneca.com/country-sites/mexico.html> no grant number). The Shahedieh cohort was partly funded by the National Institute for Medical Research (no website) development Grant N°976725. The funding sources had no involvement in the study design, data collection, analysis and interpretation, writing of the report, or decision to submit the article for publication.

**Competing interests:** The baseline CoLaus/PsyCoLaus study (2003-2006) was supported by an unrestricted research grant from GlaxoSmithKline. The funding source had no involvement in the study design, data collection, analysis and interpretation, writing of the report, or decision to submit the article for publication. This does not alter our adherence to PLoS One policies on sharing data and materials. The Tlalpan 2020 study received funding from AstraZeneca Mexico (no grant number). The funding source had no involvement in our study design, data collection, analysis and interpretation, writing of the report or decision to submit the article for publication. This does not alter our adherence to PLoS One policies on sharing data and materials.

Diagnostic capacity of our score was better than the Balkau score and comparable to the Kahn clinical one.

## Conclusion

Our clinically-based score shows encouraging results compared to other scores and can be used in populations with differing diabetes prevalence.

## Introduction

Diabetes mellitus is an important cause of morbidity, mortality and costs [1]. According to the NCD Risk factor Collaboration, the number of adults with diabetes worldwide increased from 108 million in 1980 to 422 million in 2014 [1]. Most new cases of diabetes will occur in low and middle-income countries, mainly due to the escalating prevalence of adiposity, rapidly changing dietary and physical activity behaviors, and lack of or late identification of people at risk of diabetes. Indeed, in low-income countries such as India, the prevalence of diabetes could be as high as 19.9% [2].

Early identification of people at risk of diabetes is paramount for adequate prevention by changes in lifestyle, and, if necessary, complemented by treatment. Thus, it is important to have an easily obtainable, inexpensive and reliable diabetes risk score. A review conducted in 2011 [3] identified as many as 145 diabetes risk models or scores and suggested that this number increases monthly. Among the 94 risk prediction models studied, 40 were based on biological variables [3]. Inclusion of biological variables in diabetes risk scores has a dual effect: it slightly improves the scores’ performances [4], but it also increases costs (staff and laboratory) and time (blood sampling, waiting for results). In a previous study, we have shown that the use of a diabetes risk score including biological variables cost an additional US \$ 12.02 per patient compared to a score based on clinical data only [5]. Hence, in countries most affected by the current diabetes epidemic, the use of diabetes risk scores including biological variables may not be possible due to financial or laboratory constraints.

Thus, our first aim was to derive a diabetes risk score based solely on easily obtainable clinical data, and to validate it in a similar European population by comparing it with existing clinical scores. Our second aim was to examine the validity of our score regarding clinical utility and application on populations with different diabetes and obesity prevalence, and lesser economical means, using two different cohorts from Iran and Mexico.

## Materials and methods

### Sampling procedure

The CoLaus/PsyCoLaus study is a prospective population-based study intended to evaluate the prevalence and determinants of cardiovascular disease in the population of Lausanne, Switzerland. Details of the sampling procedure have been previously documented [6] and can be accessed online ([www.colaus-psycolaus.ch](http://www.colaus-psycolaus.ch)). The source population was all adults aged 35 to 75 years in the Lausanne population register. A simple non-stratified random sample of 35% of the source population was drawn and an invitation letter sent. If the latter went unanswered, a second letter was sent and, if unanswered, several phone calls were performed. Recruitment began in June 2003 and ended in May 2006, enrolling 6733 participants who underwent an interview, a physical exam, and a blood analysis. The first follow-up was performed between April 2009 and September 2012, a mean of 5.6 years after the collection of baseline data. The

second follow-up was performed between May 2014 and July 2016, a mean of 10.9 years after the collection of baseline data.

### Clinical and biological data

All participants were examined in the morning after a fast of at least 8 hours. They were probed about their personal and family history of cardiovascular disease and cardiovascular risk factors. All prescribed and over-the-counter medicines were collected via questionnaire. Smoking status was categorized as never, former (irrespective of the time since quitting) and current (irrespective of the amount smoked). Educational level was categorized as low (primary), middle (apprenticeship), upper middle (high school), and high (university) for highest completed level of education. Physical activity was defined by exercising at least twice per week for at least 20 minutes per session.

Body weight and height were measured with participants barefoot and in light indoor clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca scale (Hamburg, Germany). Height was measured to the nearest 5 mm using a Seca (Hamburg, Germany) height gauge. Waist circumference was measured mid-way between the lowest rib and the iliac crest using a non-stretchable tape and the mean of two measurements was taken. Blood pressure (BP) was measured using an Omron HEM-907 automated oscillometric sphygmomanometer after at least a 10-minute rest in a seated position, and the mean of the last two measurements was used. Hypertension was defined by a SBP  $\geq 130$  mm Hg or a DBP  $\geq 85$  mm Hg or presence of antihypertensive drug treatment. Based on the review by Noble et al., the 130/85 mmHg threshold was preferred to the 140/90 mmHg one. High resting heart rate was defined by  $\geq 68$  beats per minute in men and  $\geq 70$  beats per minute in women.

Venous blood samples (50 mL) were drawn in the fasting state. Most biological assays were performed at the clinical laboratory of the Lausanne university hospital within 2 hours of blood collection. Glucose was assessed by glucose dehydrogenase with a maximum inter- and intra-assay CV of 2.1% and 1.0%, respectively; glycated hemoglobin (HbA1c) was assessed by HPLC (Bio-Rad, D-10TM, Reinach, Switzerland); total cholesterol by CHOD-PAP (1.6%-1.7%); HDL-cholesterol by CHOD-PAP + PEG + cyclodextrin (3.6%-0.9%); triglycerides by GPO-PAP (2.9%-1.5%).

### Incident diabetes mellitus

Two definitions of incident diabetes were used: 1) fasting glucose level  $\geq 7$  mmol/L and/or presence of an oral antidiabetic or insulin treatment, and 2) an HbA1c  $\geq 6.5\%$  (48 mmol/mol) and/or presence of an oral antidiabetic or insulin treatment. As HbA1c was assessed only in the last follow-up, analyses were restricted to participants who attended the second follow-up.

### Other clinically-based diabetes mellitus risk scores for comparison

Two diabetes risk scores based solely on clinical data were considered: the score by Balkau et al. [7] derived from a French population and the clinical score by Kahn et al. [8] derived from a United States population (S1 Table). The score by Balkau et al. is based on five variables, and the score by Kahn et al. is based on eight variables. Both scores had been tested previously in our cohort [5].

### Inclusion and exclusion criteria

The original inclusion criteria into the CoLaus/PsyCoLaus Study were: 1) written informed consent; 2) willingness to take part in the examination and to provide blood samples; 3) French

language ability. For this study, the following exclusion criteria were applied: 1) participants with type 1 and 2 diabetes at baseline; 2) no follow-up and 3) missing data for calculation of scores.

### Statistical analysis

Statistical analyses were conducted using Stata version 15.1 for Windows (Stata Corp, College Station, Texas, USA). Participants characteristics were expressed as number (percentage) for categorical variables or as mean±standard deviation for continuous variables. Between-group comparisons were performed using chi-square or Fisher's exact test for categorical variables and student's t-test for continuous variables. Multivariate analysis was conducted using logistic regression; to facilitate future scoring, all continuous variables (i.e. age, BMI, waist. . .) were categorized. Goodness of fit was assessed using the Hosmer-Lemeshow test with 10 categories; model quality was estimated using the Akaike and the Bayesian information criteria (AIC and BIC, respectively). For anthropometric data, models including only one of each parameter were computed, and the parameter providing the highest percentage of variance explained (pseudo- $R^2$ ) was selected. The diabetes risk score was created taking into account the contribution of each variable significantly associated with diabetes in the logistic model. The score was built as the sum of assigned points, defined as the OR rounded to the nearest integer, as performed in another setting [9]. The best threshold to define a high risk of diabetes was based after visual examination of the graphs displaying the values of sensitivity, specificity, positive and negative predictive values according to the score values, priority being given to a high specificity and a high negative predictive value.

The diagnostic capacity of the different scores was assessed by the AUC [area under the ROC (receiver operating characteristic) curve] and corresponding 95% confidence intervals (CI). Comparisons between scores were performed using the **roccomp** command of Stata. Sensitivity, specificity, positive and negative predictive values and their corresponding 95% CIs were computed using incident diabetes (definition 1) as gold standard. The number needed to screen (NNS) to detect one case of diabetes was computed as the number of detected diabetes cases (i.e. true positives) divided by the total number of participants screened. Statistical significance was assessed for a two-sided test with  $p < 0.05$ .

As women with gestational diabetes are at higher risk of developing diabetes type 2, a last sensitivity analysis was performed after excluding women with personal history of gestational diabetes.

### External validation cohorts

The performance of our diabetes risk score relative to two other clinically based diabetes risk scores was assessed in three cohorts. The European cohort included data from four countries (France, Germany, Netherlands and UK) of the EPIC-Europe cohort study [10]; these four countries were included because all relevant variables were available. Incident diabetes was defined using multiple sources of evidence including self-report, linkage to primary-care registers, secondary-care registers, medication use, hospital admissions and mortality data [11]. Tlalpan 2020 is a cohort of participating Mexico City residents recruited through promotional strategies in Mexico City, Mexico [12]; incident diabetes was defined as a fasting plasma glucose  $\geq 7$  mmol/L. The Shahedieh cohort study included data from a population-based survey in the province of Yazd, Iran [13] where incident diabetes was defined as a fasting plasma glucose  $\geq 7$  mmol/L.

We report our results according to the TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) statement [14].

## Ethical considerations

The institutional Ethics Committee of the University of Lausanne, which afterwards became the Ethics Commission of Canton Vaud (<http://www.cer-vd.ch>) approved the baseline CoLaus/PsyCoLaus study (reference 16/03, decisions of January 13 and February 10, 2003); the approval was renewed for the first (reference 33/09, decision of February 23, 2009) and the second (reference 26/14, decision of March 11, 2014) follow-up.

The institutional review boards for the various EPIC cohorts are the following: United Kingdom: Norfolk Research Ethics Committee; France: CNIL (Commission nationale de l'informatique et des libertés); Netherlands: Bilthoven Medical Ethical Committee of TNO Nutrition and Food Research; Institutional Review Board of the University Medical Center Utrecht; Germany: Ethical committee of the State of Brandenburg, Germany.

The Institutional Bioethics Committee of the INCICH, within the ethical framework of the seventh revision of the Declaration of Helsinki and the Regulations of the General Health Law in Matters of Research for Health of Mexico, approved the Tlalpan 2020 study of the incidence of systemic hypertension in a cohort of Mexico City residents and the written consent formats, under number 13–802 on February 19, 2013; since then, protocol and writer consent had been renewed yearly (September 23, 2014; November 17, 2015; September 13, 2016; May 16, 2017; September 26, 2018).

The institutional Ethics Committee of Digestive Disease Research Institute at Tehran University of Medical Sciences (<http://ethics.research.ac.ir/>) approved the baseline Shahedieh cohort study (reference: IR.TUMS.DDRI.Rec.1396.1); the approval was renewed for the first follow-up (reference IR.SSU. Rec.1397.135, decision of January 22, 2019).

All studies were performed in agreement with the Helsinki declaration and its former amendments. All participants gave their signed informed consent before entering the studies.

## Results

### Characteristics of participants

Of the initial 6733 patients, 21.6% were excluded, leaving 5277 participants (78.4%) for analysis. The reasons for exclusion are summarized in [Fig 1](#) and the comparison between excluded and included participants is provided in [S2 Table](#). Excluded participants were older, with higher BMI and waist circumference. They were also more frequently men, sedentary, of lower educational level, former or current smokers, with higher alcohol consumption, with a personal history of CVD, hypertension and lipid lowering drugs, and with a parental or family history of diabetes.

### Incidence of diabetes and score components

Between baseline and second follow-up, 405 participants (7.7%) developed diabetes as based on fasting plasma glucose. The bivariate comparison of 19 candidate variables between participants who developed and who remained free of diabetes is summarized in [Table 1](#). In both genders, participants who developed diabetes were older, with higher BMI, waist, waist to height and waist to hip ratios. Participants who developed diabetes were also of lower educational level, had a higher frequency of hypertension, lipid lowering drugs, personal history of CVD and family history of diabetes, and a lower frequency of leisure-time physical activity ([Table 1](#)).

The variables significantly associated with incident diabetes on bivariate analysis were introduced in a multivariable logistic regression model. Based on the results of the logistic regression and the percentage of variance explained, the following variables were selected for




Fig 1. Flowchart of the participants of the CoLaus/PsyCoLaus study.

<https://doi.org/10.1371/journal.pone.0218933.g001>

the diabetes risk score: gender, age, waist circumference, hypertension, family history of diabetes, and physical activity. The scoring system is provided in Table 2. First, we developed a separate scoring system for men and women. Nevertheless, as we wanted to keep the score as simple as possible, we developed a final scoring, applicable to either sex. The odd ratios enabling the scores are provided in S3 Table. Waist was the most important determinant of incident diabetes, while no increasing effect of age categories were found. The threshold of 13 points provided the best combination of sensitivity and specificity.

The comparison between our scoring system and the other diabetes risk scores for the CoLaus/PsyCoLaus study is provided in Table 3. Based on the AUC; our score performed better than the score by Balkau et al., while no differences were found with the score by Kahn et al. Similar findings were observed when the analysis was split by gender. The results of the diagnostic capacity of the different scores, overall and stratified by gender are provided in Table 4. Compared to the score by Balkau et al., our score had a higher sensitivity and negative predictive value, but a lower specificity. Compared to the score by Kahn et al., our score had comparable diagnostic capacities, and a slightly better specificity (Table 4). Similar findings were observed when the analysis was split by gender (Table 4). The goodness of fit and information criteria are provided in S4 Table.

**Table 1. Bivariate analysis of the factors associated with incident diabetes mellitus, stratified by gender.** CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.

	Women		P-value	Men		P-value
	Non-diabetic	Diabetic		Non-diabetic	Diabetic	
Sample size	2755	149		2117	256	
Age (years)	52.2 ± 10.5	57.5 ± 9	<0.001	50.5 ± 10.3	54.9 ± 10.1	<0.001
Anthropometry						
Height (cm)	163 ± 7	162 ± 6	0.016	175 ± 7	174 ± 7	0.011
Weight (kg)	64.9 ± 11.7	75.9 ± 13.6	<0.001	79.7 ± 12	86.3 ± 13.2	<0.001
Body mass index (kg/cm <sup>2</sup> )	24.5 ± 4.3	29.1 ± 5.0	<0.001	25.9 ± 3.5	28.4 ± 3.9	<0.001
Waist circumference (cm)	81.6 ± 11.1	95.0 ± 12.5	<0.001	93.5 ± 10	100.9 ± 10.3	<0.001
Waist to height ratio	50.2 ± 7.2	58.9 ± 8.0	<0.001	53.4 ± 5.8	58.0 ± 6.0	<0.001
Waist to hip ratio	0.82 ± 0.07	0.88 ± 0.06	<0.001	0.92 ± 0.06	0.95 ± 0.05	<0.001
Educational level			0.001			<0.001
University	494 (17.9)	13 (8.7)		573 (27.1)	41 (16.0)	
High school	730 (26.5)	33 (22.2)		523 (24.7)	55 (21.5)	
Apprenticeship	969 (35.2)	57 (38.3)		735 (34.7)	106 (41.4)	
Mandatory education	562 (20.4)	46 (30.9)		286 (13.5)	54 (21.1)	
Smoking status			0.434			0.024
Never	1292 (46.9)	62 (41.6)		758 (35.8)	70 (27.3)	
Former	785 (28.5)	48 (32.2)		779 (36.8)	103 (40.2)	
Current	678 (24.6)	39 (26.2)		580 (27.4)	83 (32.4)	
BP ≥ 130/85 mm Hg	963 (35.0)	92 (61.7)	<0.001	1026 (48.5)	172 (67.2)	<0.001
Hypertension †	1063 (38.6)	101 (67.8)	<0.001	1100 (52.0)	193 (75.4)	<0.001
High resting heart rate ‡	1155 (41.9)	62 (41.6)	0.940	892 (42.1)	127 (49.6)	0.022
Lipid lowering drugs	216 (7.8)	26 (17.5)	<0.001	222 (10.5)	44 (17.2)	0.001
Alcohol ≥35 drinks/week	9 (0.3)	0 (0)	1.00 §	60 (2.8)	14 (5.5)	0.022
Caffeinated drinks (units/day)			0.644			0.197
None	178 (6.5)	12 (8.1)		128 (6.1)	13 (5.1)	
1–3	1819 (66.0)	94 (63.1)		1350 (63.8)	170 (66.4)	
4–6	654 (23.7)	35 (23.5)		533 (25.2)	54 (21.1)	
>6	104 (3.8)	8 (5.4)		106 (5.0)	19 (7.4)	
Leisure-time PA ≥2/week	1599 (58.0)	67 (45.0)	0.002	1162 (54.9)	114 (44.5)	0.002
Personal history of CVD	116 (4.2)	13 (8.7)	0.009	110 (5.2)	27 (10.6)	0.001
Parental history of diabetes			<0.001 §			0.015 §
No	2262 (82.1)	99 (66.4)		1777 (83.9)	195 (76.2)	
Mother only	262 (9.5)	26 (17.5)		164 (7.8)	31 (12.1)	
Father only	210 (7.6)	21 (14.1)		165 (7.8)	28 (10.9)	
Both	21 (0.8)	3 (2.0)		11 (0.5)	2 (0.8)	
Family history of diabetes						
Type 1+2	612 (22.2)	65 (43.6)	<0.001	402 (19.0)	72 (28.1)	0.001
Type 2	586 (21.3)	64 (43.0)	<0.001	390 (18.4)	71 (27.7)	<0.001

BP, blood pressure; CVD, cardiovascular disease; PA, physical activity.

† defined by SBP ≥ 130 mm Hg or DBP ≥ 85 mm Hg or presence of antihypertensive drug treatment;

‡, defined by ≥ 68 beats per minute in men and ≥ 70 beats per minute in women.

Results are expressed as mean ± standard deviation or as number of participants (%). Between-group comparisons performed using student's t-test for continuous variables and chi-square or Fisher's exact test (§) for categorical variables.

<https://doi.org/10.1371/journal.pone.0218933.t001>

**Table 2. Clinical score for predicting type 2 diabetes mellitus risk.**

	Men	Women	Final scoring
Male gender	-	-	2
Age group (years)			
[45–54]	2	3	2
[55–64]	2	3	2
[65–75]	2	3	2
Waist (cm)			
70–79 W, 80–89 M	3	2	2
80–89 W, 90–99 M	6	6	6
90–99 W, 100–109 M	12	12	12
100–109 W, 110–120 M	14	22	18
110+ W, 120+ M	32	31	32
Family history of diabetes §	2	2	2
Physical inactivity ‡	1	1	1
Hypertension †	2	2	2

M, men; W, women.

§: father, mother or siblings;

‡: less than twice 20 minutes leisure physical activity per week;

†: systolic blood pressure  $\geq$  130 mm Hg and/or diastolic blood pressure  $\geq$  85 mmHg and/or antihypertensive drug treatment.

<https://doi.org/10.1371/journal.pone.0218933.t002>

### Sensitivity analysis

A sensitivity analysis was performed using diabetes based on HbA1c. Of the 4297 participants devoid of diabetes at baseline and who came to the second follow-up, 255 (5.9%) developed diabetes based on HbA1c. The results are summarized in S5 and S6 Tables. Our score showed a higher AUC than the score by Balkau et al., while no differences were found with the score by Kahn et al. (S5 Table), and similar findings were observed for the diagnostic capacity (S6 Table).

Sensitivity analysis after excluding 30 women with personal history of gestational diabetes led to similar findings (S7 and S8 Tables).

### External validation cohorts

The characteristics of the different external validation cohorts are summarized in S9–S11 Tables. The results of our diabetes risk score compared with the other two clinically based diabetes risk scores for each of the three cohorts (European, Tlalpan 2020 and Shahedieh) are summarized in S12 and S13 Tables. Based on the AUC, our score performed better than both scores in the Tlalpan 2020 cohort, better than Kahn et al. on the Shahedieh cohort but performed less well in the European cohort (S12 Table). Our score had a better sensitivity and negative predictive value and a lower specificity and positive predictive value than the score of Balkau et al; the diagnostic capacity was similar to the score by Kahn et al. (S13 Table).

### Discussion

Our score provides an easy way of screening people at risk of developing diabetes; further, and contrary to many other scores [3], it was replicated in other cohorts in Europe and in two developing countries.

**Table 3. Areas under the receiver operating characteristic (ROC) curves and incidence of diabetes per quintile of diabetes risk estimation score, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

	AUC (95% CI)	P-value §	First	Second	Third	Fourth	Fifth
<b>All participants</b>							
CoLaus/PsyCoLaus	0.772 (0.750–0.794)		1.0	3.0	6.0	10.8	20.2
Balkau	0.748 (0.726–0.770)	<0.001	1.0	5.0	9.1	NA	19.7
Kahn clinic	0.774 (0.753–0.796)	0.668	0.7	2.5	5.4	10.7	20.0
<b>Women (n = 2904)</b>							
CoLaus/PsyCoLaus	0.806 (0.772–0.840)		0.8	2.4	4.3	7.2	18.4
Balkau	0.788 (0.753–0.822)	0.024	0.8	2.8	6.4	NA	16.9
Kahn clinic	0.807 (0.774–0.839)	0.948	0.4	1.5	4.6	7.6	17.8
<b>Men (n = 2373)</b>							
CoLaus/PsyCoLaus	0.719 (0.688–0.751)		1.8	3.9	7.3	13.6	21.5
Balkau	0.700 (0.670–0.730)	0.065	1.6	7.8	11.5	NA	22.2
Kahn clinic	0.728 (0.698–0.758)	0.283	1.5	4.2	6.4	13.9	21.4

Results are expressed as area under the curve and (95% confidence interval), and as percentage of participants developing diabetes during the 10.9 year follow-up. Diabetes was defined as fasting glucose level  $\geq 7$  mmol/L and/or presence of an oral antidiabetic or insulin treatment

<https://doi.org/10.1371/journal.pone.0218933.t003>

### Variables in the model

A previous systematic review identified 29 clinical (i.e. non biological) variables associated with incident diabetes [3]. In this study, we were able to assess the predictive capacity of 19 of them, and six were selected for the final model.

**Table 4. Diagnostic capacity of the different scores, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

	Threshold	Sensitivity	Specificity	Positive PV	Negative PV	N needed to screen
<b>All participants</b>						
CoLaus/PsyCoLaus	13	60.5 (55.5–65.3)	77.1 (75.8–78.2)	18.0 (16.0–20.1)	95.9 (95.2–96.5)	22
Balkau	5	10.1 (7.4–13.5)	97.4 (96.9–97.8)	24.4 (18.1–31.6)	92.9 (92.1–93.6)	129
Kahn clinic	38	64.0 (59.1–68.6)	74.6 (73.4–75.8)	17.3 (15.4–19.3)	96.1 (95.5–96.7)	20
<b>Women (n = 2904)</b>						
CoLaus/PsyCoLaus	13	66.4 (58.3–74.0)	79.8 (78.2–81.3)	15.1 (12.4–18.1)	97.8 (97.1–98.3)	29
Balkau	5	13.4 (8.4–20.0)	97.9 (97.3–98.4)	26.0 (16.6–37.2)	95.4 (94.6–96.2)	145
Kahn clinic	38	62.4 (54.1–70.2)	80.7 (79.1–82.1)	14.9 (12.2–17.9)	97.5 (96.8–98.1)	31
<b>Men (n = 2373)</b>						
CoLaus/PsyCoLaus	13	57.0 (50.7–63.2)	73.5 (71.6–75.4)	20.7 (17.7–23.8)	93.4 (92.1–94.5)	16
Balkau	5	8.2 (5.2–12.3)	96.7 (95.8–97.4)	23.1 (14.9–33.1)	89.7 (88.4–90.9)	113
Kahn clinic	38	64.8 (58.7–70.7)	66.8 (64.7–68.8)	19.1 (16.5–21.9)	94.0 (92.7–95.2)	14

PV, predictive value; N, number. Results are expressed as value and (95% confidence interval). Number needed to screen to detect one true incident case of diabetes mellitus was computed as number of participants screened/number of participants who developed diabetes and who scored positive

<https://doi.org/10.1371/journal.pone.0218933.t004>

Age was included in the model, as it is in most risk assessment models [8, 15–17]. The risk of diabetes increases with age [18], although in our model no such increase in risk was found. A possible explanation is that other factors such as waist or physical inactivity also increase with age [19, 20], thus cancelling the age-specific increase in diabetes risk.

Gender was also included in the model, as in other scores [7, 17]. Indeed, male sex is associated with a higher risk of diabetes independently of other risk factors [21].

Waist circumference was the obesity measure selected for our score, as it is also used in many other scores [7, 8, 15, 16]. Waist circumference was by far the strongest variable in our score, a finding in agreement with the literature, where abdominal obesity has been found to be the strongest adiposity determinant of diabetes [22, 23]. Importantly, the sole presence of a high waist circumference was enough to consider a subject as at high risk of diabetes, suggesting that waist measurement could already provide important information regarding the risk of diabetes, as it is the case for other populations such as in India [24], or Brazil [25].

Hypertension was included in our score, as it was in many other diabetes risk scores [7, 8, 15–17]. Hypertension is known to be associated with development of diabetes [26–28]. For our score, we defined hypertension as a SBP  $\geq$  130 mm Hg or DBP  $\geq$  85 mm Hg or the presence of antihypertensive drug treatment, but different possible definitions (measured; anamnestic; hypertension medication) have been used [7, 8, 15–17]. We chose to use measured hypertension in our score as this condition is also very prevalent in the general population [29] and is a major risk factor for cardiovascular disease [30]. Hence, assessing risk of diabetes using our score would also help to detect (and manage) hypertension.

Family history of diabetes is generally easy to obtain and was included in our score, as it is in most scores [7, 8, 15, 17]. The presence of a positive family history underlines a genetic component to diabetes but can also reflect the lifestyle or the environmental conditions people were used to during their upbringing [31].

Lack of physical activity was included in the score, as it is also in some other scores. [15, 16]. Physical activity is hard to categorize using a standard procedure; indeed, in this study, it was not possible to obtain a homogeneous definition for physical activity within all cohorts, see S14 Table [32, 33]. Still, irrespective of this limitation, the results were quite similar between cohorts. Hence, our results suggest that even a bold definition of physical activity may suffice to predict the risk of diabetes. This should encourage people to be more active because it underlines that even a small amount of physical activity is better than nothing [34].

## Comparison with other scores

When using CoLaus/PsyCoLaus data, the AUC of our score performed better than the one by Balkau et al. and similarly to Kahn clinic. Our score's sensitivity was higher than Balkau's and similar to Kahn's clinical score. Our specificity was inferior to Balkau's but similar to Kahn's clinical score. The positive and negative predictive values were similar to Kahn's. Although the score by Balkau et al. showed the highest specificity among all cohorts, it led to a considerable underestimation of the prevalence of subjects at risk. For instance, in Iran, the prevalence of subjects at risk according to the score of Balkau et al. was considerably lower than the reported prevalence of diabetes (11.37%) [35].

Overall, our results suggest that our score performs equally well or even better than existing ones. Importantly, the number needed to screen was considerably lower than obtained using the score by Balkau et al., and comparable to the score by Kahn et al. This has important consequences for screening, as it suggests that, for a given number of people screened, a higher number of people who will develop diabetes will be detected.

## Strengths and limitations

The main strength of our study is that the score was replicated on three cohorts from different continents with contrasting diabetes prevalence [36] (S15 Table), a control seldom performed for other scores [3]. Indeed, our score's AUC in these cohorts is comparable or better than Balkau et al.'s and Kahn et al.'s. Secondly, our score performs similarly to Kahn's clinical score, but with a smaller number of variables. Importantly, the previous review indicated that many models and scores were not used because they required tests not routinely available or were developed without a specific user in mind [3]. Our score overcomes those two limitations, as it is based on easily accessible data, which could be collected by non-medical professionals. Hence, it could be implemented worldwide with little effort. A third strength is that obesity prevalence in women was different in each replication cohort, which reinforces our score. In men, however, average waist circumference was very similar among the cohorts. Fourthly, although part of the type 2 diabetes epidemic is due to environmental factors, our score is important on a personal level. Indeed, if one calculates one's diabetes score and it is elevated, every individual can decide to act upon the three modifiable variables (hypertension, waist circumference and physical activity). Fifthly, the scoring system could be adapted to the characteristics of the populations, by changing the threshold and/or the weights of its parameters, as it has been done for cardiovascular risk scores [37]. Sixthly, the American Diabetes Association (ADA) recommends testing all people, beginning at age 45 years.[38] The CoLaus/PsyColaus sample included adults aged 35 to 75, which is within the recommended age frame. Finally, our score includes 4 of the 9 criteria issued by the ADA recommendations for testing diabetes or prediabetes in asymptomatic adults: overweight, hypertension, family history, physical inactivity.[38] This shows the importance of these variables in the development of diabetes.

This study also has some limitations worth acknowledging. Firstly, participants excluded from the analysis presented higher prevalence of several components of the diabetes risk score. Hence, it is likely that the impact of some components might have been different, had those participants been included in the analysis. Still, external validation of the analysis in other cohorts led to similar findings. Secondly, the number of incident diabetes cases was relatively low in the Shahedieh cohort, a finding likely due to a short follow-up time (1 year) and leading to a lower statistical power. Hence, it would be of interest to replicate the analysis in the forthcoming years with a larger number of incident diabetes cases. Thirdly, we were unable to validate our score on a South-Eastern Asian country, where waist circumference is considered as a major determinant of diabetes [39]. Still, given the importance of waist circumference in our score, we hypothesize that it would perform relatively well in those countries, although an external validation study in a South-Eastern Asian country is necessary to test this hypothesis, especially in the genetically lean Asian men. Fourthly, physical activity was assessed differently in each cohort (S14 Table). Assessing physical activity in a standardized manner is a difficult task, and there is even lack of standardization when physical activity is measured using accelerometry [40]. Hence, we chose a very pragmatic solution, where each cohort would define physical activity according to its own standards. We acknowledge that this procedure increases variability between cohorts, but on the other hand it allows the use of our score by many other cohorts. Fifthly, our score uses a fixed weight for all risk factors independently of the country considered, while it has been suggested that the importance of conventional risk factors for predicting diabetes varies between countries [41]. Indeed, levels of diabetes have been shown to vary according to socio-economic status [42] and ethnicity [43]. However, in our study, neither ethnicity nor education came out as significant predictors for type 2 diabetes. Further, waist circumference has been shown to be the best anthropometric predictor across all racial and ethnic groups [44]. Moreover, due to its simple scoring system, our score allows the

addition of other risk factors if the latter are considered as important in a given setting. Alternatively, it might be necessary to recalibrate our score according to country, as it has been suggested for cardiovascular risk prediction [37]. Finally, as other scores, ours did not allow the identification of all incident cases of diabetes. Still, it can be used with minimal clinical data, and can thus be applied in settings with limited health resources where no screening for diabetes risk is available.

## Conclusion

Our clinically-based score shows comparable or even better results to other clinical scores and can be used on different populations with contrasting diabetes prevalence.

## Supporting information

**S1 Table. Characteristics of the diabetes risk scores.**

(DOCX)

**S2 Table. Baseline characteristics of included and excluded participants, CoLaus/PsyCoLaus study, Lausanne, Switzerland.**

(DOCX)

**S3 Table. Results of the logistic regression using incident diabetes as dependent variable, both genders, CoLaus/PsyCoLaus study.**

(DOCX)

**S4 Table. Goodness of fit and information criteria for each diabetes risk score, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland.**

(DOCX)

**S5 Table. Areas under the ROC and incidence of diabetes as defined by glycated haemoglobin, per quintile of diabetes risk estimation score, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

(DOCX)

**S6 Table. Diagnostic capacity of the different scores, overall and stratified by gender, using diabetes as defined by glycated haemoglobin, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

(DOCX)

**S7 Table. Areas under the receiver operating characteristic (ROC) curves and incidence of diabetes per quintile of diabetes risk estimation score, women without history of gestational diabetes (n = 2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

(DOCX)

**S8 Table. Diagnostic capacity of the different scores, women without history of gestational diabetes (n = 2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.**

(DOCX)

**S9 Table. Characteristics of the four countries (France, Germany, Netherlands and UK) contributing data from the EPIC-Europe cohort study.**

(DOCX)

**S10 Table. Characteristics of the Tlalpan 2020 cohort, Mexico City, Mexico.**

(DOCX)

**S11 Table. Characteristics of the Shahedieh cohort, Iran.**  
(DOCX)

**S12 Table. Performance of the new score and of two other clinically based scores, in original cohort (CoLaus/PsyCoLaus) and in the replication cohorts.**  
(DOCX)

**S13 Table. Diagnostic capacity of the new score and of two other clinically based scores, in original cohort (CoLaus/PsyCoLaus) and in the replication cohorts.**  
(DOCX)

**S14 Table. Definitions of physical activity in the original and in the replication cohorts.**  
(DOCX)

**S15 Table. Diabetes prevalence in percentage of adults in 2014 classified by country and gender.**  
(DOCX)

## Acknowledgments

The authors would like to thank the following EPIC-Europe centres for providing data for use in the replication study: Norfolk, France, Bilthoven, Utrecht and Potsdam. They also thank Tlalpan 2020 study team for their contribution and Janko Fabecic, student at the Faculty of Biology and Medicine, University of Lausanne, Switzerland for sharing his bibliography on diabetes scores.

## Author Contributions

**Conceptualization:** Vanessa Kraege, Marie Méan, Pedro Marques-Vidal.

**Data curation:** Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei, Pedro Marques-Vidal.

**Formal analysis:** Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei, Pedro Marques-Vidal.

**Funding acquisition:** Peter Vollenweider, Gérard Waeber.

**Investigation:** Vanessa Kraege, Peter Vollenweider, Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei.

**Methodology:** Vanessa Kraege, Pedro Marques-Vidal.

**Project administration:** Vanessa Kraege.

**Resources:** Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei.

**Supervision:** Marie Méan.

**Validation:** Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei.

**Visualization:** Pedro Marques-Vidal.

**Writing – original draft:** Vanessa Kraege.

**Writing – review & editing:** Peter Vollenweider, Gérard Waeber, Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei, Marie Méan.

## References

1. N. C. D. Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016; 387(10027):1513–30. [https://doi.org/10.1016/S0140-6736\(16\)00618-8](https://doi.org/10.1016/S0140-6736(16)00618-8) PMID: 27061677
2. Geldsetzer P, Manne-Goehler J, Theilmann M, Davies JJ, Awasthi A, Vollmer S, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. *JAMA Intern Med*. 2018; 178(3):363–72. <https://doi.org/10.1001/jamainternmed.2017.8094> PMID: 29379964
3. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. *Bmj*. 2011; 343:d7163. <https://doi.org/10.1136/bmj.d7163> PMID: 22123912
4. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. *Bmj*. 2012; 345:e5900. <https://doi.org/10.1136/bmj.e5900> PMID: 22990994
5. Schmid R, Vollenweider P, Bastardot F, Waeber G, Marques-Vidal P. Validation of 7 type 2 diabetes mellitus risk scores in a population-based cohort: CoLaus study. *Arch Intern Med*. 2012; 172(2):188–9. <https://doi.org/10.1001/archinte.172.2.188> PMID: 22271131
6. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord*. 2008; 8:6. <https://doi.org/10.1186/1471-2261-8-6> PMID: 18366642
7. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care*. 2008; 31(10):2056–61. <https://doi.org/10.2337/dc08-0368> PMID: 18689695
8. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. *Ann Intern Med*. 2009; 150(11):741–51. <https://doi.org/10.7326/0003-4819-150-11-200906020-00002> PMID: 19487709
9. Marti-Soler H, Hirotsu C, Marques-Vidal P, Vollenweider P, Waeber G, Preisig M, et al. The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study. *Lancet Respir Med*. 2016; 4(9):742–8. [https://doi.org/10.1016/S2213-2600\(16\)30075-3](https://doi.org/10.1016/S2213-2600(16)30075-3) PMID: 27321086
10. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer*. 2004; 4(3):206–15. <https://doi.org/10.1038/nrc1298> PMID: 14993902
11. InterAct C, Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, et al. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia*. 2011; 54(9):2272–82. <https://doi.org/10.1007/s00125-011-2182-9> PMID: 21717116
12. Colin-Ramirez E, Rivera-Mancia S, Infante-Vazquez O, Cartas-Rosado R, Vargas-Barron J, Madero M, et al. Protocol for a prospective longitudinal study of risk factors for hypertension incidence in a Mexico City population: the Tlalpan 2020 cohort. *BMJ Open*. 2017; 7(7):e016773. <https://doi.org/10.1136/bmjopen-2017-016773> PMID: 28760800
13. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshk AA, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. *Am J Epidemiol*. 2018; 187(4):647–55. <https://doi.org/10.1093/aje/kwx314> PMID: 29145581
14. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *Bmj*. 2015; 350:g7594. <https://doi.org/10.1136/bmj.g7594> PMID: 25569120
15. Diabète Suisse. Test diabète Baden, Switzerland 2017 <https://www.diabetesschweiz.ch/fr/le-diabete/test-diabete/>.
16. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care*. 2003; 26(3):725–31. <https://doi.org/10.2337/diacare.26.3.725> PMID: 12610029

17. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. *Diabetes Metab Res Rev*. 2000; 16(3):164–71. PMID: [10867715](https://pubmed.ncbi.nlm.nih.gov/10867715/)
18. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004; 27(5):1047–53. <https://doi.org/10.2337/diacare.27.5.1047> PMID: [15111519](https://pubmed.ncbi.nlm.nih.gov/15111519/)
19. Stevens J, Katz EG, Huxley RR. Associations between gender, age and waist circumference. *Eur J Clin Nutr*. 2010; 64(1):6–15. <https://doi.org/10.1038/ejcn.2009.101> PMID: [19738633](https://pubmed.ncbi.nlm.nih.gov/19738633/)
20. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. *Obes Res*. 2003; 11(10):1223–31. <https://doi.org/10.1038/oby.2003.168> PMID: [14569048](https://pubmed.ncbi.nlm.nih.gov/14569048/)
21. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev*. 2016; 37(3):278–316. <https://doi.org/10.1210/er.2015-1137> PMID: [27159875](https://pubmed.ncbi.nlm.nih.gov/27159875/)
22. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. *Am J Clin Nutr*. 2006; 84(3):483–9. <https://doi.org/10.1093/ajcn/84.3.483> PMID: [16960160](https://pubmed.ncbi.nlm.nih.gov/16960160/)
23. Borne Y, Nilsson PM, Melander O, Hedblad B, Engstrom G. Multiple anthropometric measures in relation to incidence of diabetes: a Swedish population-based cohort study. *Eur J Public Health*. 2015; 25(6):1100–5. <https://doi.org/10.1093/eurpub/ckv044> PMID: [25817208](https://pubmed.ncbi.nlm.nih.gov/25817208/)
24. Prakash K, Chandran DS, Khadgawat R, Jaryal AK, Deepak KK. Waist Circumference Rather than Body Mass Index is Better Indicator of Insulin Resistance in Type 2 Diabetes Mellitus in North Indian Population. *Indian J Physiol Pharmacol*. 2016; 60(1):52–6. PMID: [29953194](https://pubmed.ncbi.nlm.nih.gov/29953194/)
25. Alvim Rde O, Mourao-Junior CA, de Oliveira CM, Krieger JE, Mill JG, Pereira AC. Body mass index, waist circumference, body adiposity index, and risk for type 2 diabetes in two populations in Brazil: general and Amerindian. *PLoS One*. 2014; 9(6):e100223. <https://doi.org/10.1371/journal.pone.0100223> PMID: [24937307](https://pubmed.ncbi.nlm.nih.gov/24937307/)
26. Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, et al. Insufficient control of blood pressure and incident diabetes. *Diabetes Care*. 2009; 32(5):845–50. <https://doi.org/10.2337/dc08-1881> PMID: [19223610](https://pubmed.ncbi.nlm.nih.gov/19223610/)
27. Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. *Hypertens Res*. 2015; 38(11):783–9. <https://doi.org/10.1038/hr.2015.72> PMID: [26178151](https://pubmed.ncbi.nlm.nih.gov/26178151/)
28. Hayashi T, Tsumura K, Suematsu C, Endo G, Fujii S, Okada K. High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey. *Diabetes Care*. 1999; 22(10):1683–7. <https://doi.org/10.2337/diacare.22.10.1683> PMID: [10526735](https://pubmed.ncbi.nlm.nih.gov/10526735/)
29. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. *Lancet*. 2017; 389(10064):37–55. [https://doi.org/10.1016/S0140-6736\(16\)31919-5](https://doi.org/10.1016/S0140-6736(16)31919-5) PMID: [27863813](https://pubmed.ncbi.nlm.nih.gov/27863813/)
30. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018; 39(33):3021–104. <https://doi.org/10.1093/eurheartj/ehy339> PMID: [30165516](https://pubmed.ncbi.nlm.nih.gov/30165516/)
31. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC Med*. 2017; 15(1):131. <https://doi.org/10.1186/s12916-017-0901-x> PMID: [28720102](https://pubmed.ncbi.nlm.nih.gov/28720102/)
32. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Public Health Nutr*. 2003; 6(4):407–13. <https://doi.org/10.1079/PHN2002439> PMID: [12795830](https://pubmed.ncbi.nlm.nih.gov/12795830/)
33. Ipaq. <https://sites.google.com/site/theipaq/scoring-protocol>.
34. Hemmingsen B, Gimenez-Perez G, Mauricio D, Roque IFM, Metzendorf MI, Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2017; 12:CD003054. <https://doi.org/10.1002/14651858.CD003054.pub4> PMID: [29205264](https://pubmed.ncbi.nlm.nih.gov/29205264/)
35. Esteghamati A, Etamad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. *Diabetes Res Clin Pract*. 2014; 103(2):319–27. <https://doi.org/10.1016/j.diabres.2013.12.034> PMID: [24447808](https://pubmed.ncbi.nlm.nih.gov/24447808/)
36. [NCD Risk Factor Collaboration]. <http://ncdrisc.org/>.

37. Marques-Vidal P, Rodondi N, Bochud M, Chiolerio A, Pecoud A, Hayoz D, et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. *Int J Cardiol.* 2009; 133(3):346–53. <https://doi.org/10.1016/j.ijcard.2008.01.004> PMID: 18485502
38. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care.* 2018; 41(Suppl 1):S13–S27. <https://doi.org/10.2337/dc18-S002> PMID: 29222373
39. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. *Lancet.* 1991; 337(8738):382–6. [https://doi.org/10.1016/0140-6736\(91\)91164-p](https://doi.org/10.1016/0140-6736(91)91164-p) PMID: 1671422
40. Wijndaele K, Westgate K, Stephens SK, Blair SN, Bull FC, Chastin SF, et al. Utilization and Harmonization of Adult Accelerometry Data: Review and Expert Consensus. *Med Sci Sports Exerc.* 2015; 47(10):2129–39. <https://doi.org/10.1249/MSS.0000000000000661> PMID: 25785929
41. Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P, et al. Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. *Diabetes Care.* 2016; 39(5):780–7. <https://doi.org/10.2337/dc15-2338> PMID: 26965719
42. McNamara CL, Balaj M, Thomson KH, Eikemo TA, Solheim EF, Bambra C. The socioeconomic distribution of non-communicable diseases in Europe: findings from the European Social Survey (2014) special module on the social determinants of health. *Eur J Public Health.* 2017; 27(suppl\_1):22–6. <https://doi.org/10.1093/eurpub/ckw222> PMID: 28355638
43. Gujral UP, Mohan V, Pradeepa R, Deepa M, Anjana RM, Narayan KM. Ethnic differences in the prevalence of diabetes in underweight and normal weight individuals: The CARRS and NHANES studies. *Diabetes Res Clin Pract.* 2018; 146:34–40. <https://doi.org/10.1016/j.diabres.2018.09.011> PMID: 30244052
44. Luo J, Hendryx M, Laddu D, Phillips LS, Chlebowski R, LeBlanc ES, et al. Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. *Diabetes Care.* 2019; 42(1):126–33. <https://doi.org/10.2337/dc18-1413> PMID: 30352893

## Supplemental information

S1 Table. Characteristics of the diabetes risk scores

	CoLaus/PsyCoLaus score	Balkau et al. <sup>7</sup>	Kahn et al (C) <sup>8</sup>
Country		France	USA
Population number		3817	12'729
Follow-up (years)		9	9
Age	X		X
Sex	X	X	
BMI, Weight			X
Waist	X	X	X
Height			X
Hypertension*	HM/MH	HM/MH	HM/MH
Resting pulse			X
Family history of diabetes	X	X	X
History of hyperglycemia			
Steroids			
Physical activity	X		
Smoking		X	
Alcohol			X
Fruit & vegetable consumption			
Glucose level			
Triglycerides			
High density lipoproteins			
Uric acid			
Number of variables	6	5	8

\*AH: anamnestic hypertension, HM: hypertension medication; MH measured hypertension; NA, not available

## Supplemental information

**S2 Table. Baseline characteristics of included and excluded participants, CoLaus/PsyCoLaus study, Lausanne, Switzerland.**

	Included	Excluded	P-value
Sample size	5277	1456	
Woman	2904 (55.0)	640 (44.0)	<0.001
Age (years)	51.8 ± 10.5	55.4 ± 11.2	<0.001
Anthropometry			
Height (cm)	168 ± 9	168 ± 9	0.399
Weight (kg)	72.2 ± 14.3	77.6 ± 17.1	<0.001
Body mass index (kg/cm <sup>2</sup> )	25.4 ± 4.2	27.4 ± 5.3	<0.001
Waist circumference (cm)	87.7 ± 12.5	94.1 ± 14.8	<0.001
Waist to height ratio	52.1 ± 7.0	56.0 ± 8.5	<0.001
Waist to hip ratio	0.87 ± 0.08	0.91 ± 0.09	<0.001
Educational level			<0.001
University	1121 (21.2)	199 (13.8)	
High school	1341 (25.4)	284 (19.7)	
Apprenticeship	1867 (35.4)	510 (35.4)	
Mandatory education	948 (18.0)	449 (31.1)	
Smoking status			0.012
Never	2182 (41.4)	550 (37.9)	
Former	1715 (32.5)	468 (32.3)	
Current	1380 (26.2)	432 (29.8)	
Blood pressure ≥ 130/85 mm Hg	2253 (42.7)	825 (57.0)	<0.001
Hypertension †	2457 (46.6)	921 (63.6)	<0.001
High resting heart rate ‡	2236 (42.4)	731 (50.6)	<0.001
Lipid lowering drugs	508 (9.6)	277 (19.0)	<0.001
Alcohol ≥35 drinks/week	83 (1.6)	47 (3.2)	<0.001
Caffeinated drinks (units/day)			0.001
None	331 (6.3)	119 (8.2)	
1-3	3433 (65.1)	951 (65.6)	
4-6	1276 (24.2)	297 (20.5)	
>6	237 (4.5)	82 (5.7)	
Leisure-time PA ≥2/week	2942 (55.8)	653 (45.0)	<0.001
Personal history of CVD	266 (5.0)	141 (9.7)	<0.001
Parental history of diabetes			<0.001
No	4333 (82.1)	1130 (77.6)	
Mother only	483 (9.2)	184 (12.6)	
Father only	424 (8.0)	125 (8.6)	
Both	37 (0.7)	17 (1.2)	
Family history of diabetes (type 1+2)	1151 (21.8)	421 (28.9)	<0.001

## Supplemental information

**S3 Table. Results of the logistic regression using incident diabetes as dependent variable, both genders, CoLaus/PsyCoLaus study.**

	Odds ratio (95% confidence)	P-value
Male gender	2.18 (1.73 - 2.73)	<0.001
Age group (years)		
[45-54]	1.87 (1.34 - 2.60)	<0.001
[55-64]	2.18 (1.56 - 3.06)	<0.001
[65-75]	1.83 (1.24 - 2.71)	0.002
Waist (cm)		
70-79 W, 80-89 M	2.50 (0.88 - 7.04)	0.084
80-89 W, 90-99 M	6.08 (2.22 - 16.7)	<0.001
90-99 W, 100-109 M	12.1 (4.40 - 33.1)	<0.001
100-109 W, 110-120 M	18.1 (6.44 - 50.7)	<0.001
110+ W, 120+ M	31.8 (10.7 - 94.4)	<0.001
Family history of diabetes §	1.90 (1.50 - 2.39)	<0.001
Physical inactivity ‡	1.32 (1.06 - 1.64)	0.013
Hypertension †	1.61 (1.25 - 2.07)	<0.001

§: father, mother or siblings; ‡: less than twice 20 minutes leisure physical activity per week; †: systolic blood pressure  $\geq$  130 mm Hg and/or diastolic blood pressure  $\geq$  85 mmHg and/or antihypertensive drug treatment. Results are expressed as odds ratio and (95% confidence interval).

## Supplemental information

**S4 Table. Goodness of fit and information criteria for each diabetes risk score, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland.**

	Goodness of fit ‡	Akaike IC	Bayesian IC
<b>All participants</b>			
CoLaus	<0.001	2559.00	2572.14
Balkau	0.009	2552.36	2565.50
Kahn clinic	0.032	2491.39	2504.53
<b>Women (n=2904)</b>			
CoLaus	0.022	1027.01	1038.96
Balkau	0.816	1012.74	1024.69
Kahn clinic	0.046	992.69	1004.64
<b>Men (n=2373)</b>			
CoLaus	<0.001	1504.31	1515.85
Balkau	0.013	1506.33	1517.87
Kahn clinic	0.047	1477.01	1488.55

‡ p-value of Hosmer-Lemeshow test using 10 groups

## Supplemental information

S5 Table. Areas under the ROC and incidence of diabetes as defined by glycated haemoglobin, per quintile of diabetes risk estimation score, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003-2017.

	AUC (95% CI)	P-value	First	Second	Third	Fourth	Fifth
<b>All participants (4297)</b>							
CoLaus/PsyCoLaus	0.802 (0.776 - 0.827)		0.6	1.8	4.3	7.8	18.2
Balkau	0.775 (0.750 - 0.801)	0.001	0.5	-	3.4	6.9	17.7
Kahn clinic	0.805 (0.780 - 0.830)	0.596	0.4	1.2	4.2	7.0	17.5
<b>Women (n=2413)</b>							
CoLaus/PsyCoLaus	0.834 (0.799 - 0.869)		0.3	1.8	3.8	5.3	17.6
Balkau	0.817 (0.781 - 0.852)	0.070	0.2	-	2.3	5.4	15.8
Kahn clinic	0.840 (0.808 - 0.872)	0.544	0.0	0.6	4.5	4.7	17.2
<b>Men (n=1884)</b>							
CoLaus/PsyCoLaus	0.757 (0.718 - 0.795)		1.5	1.7	4.6	9.9	18.8
Balkau	0.728 (0.691 - 0.765)	0.026	1.1	-	4.8	8.3	19.4
Kahn clinic	0.762 (0.724 - 0.799)	0.580	1.3	2.2	3.8	9.5	17.7

AUC, area under the ROC. Results are expressed as value and (95% confidence interval) for AUC and as percentage for the incidence of diabetes. Comparison of AUC performed using the **roccomp** procedure of Stata.

## Supplemental information

S6 Table. Diagnostic capacity of the different scores, overall and stratified by gender, using diabetes as defined by glycosylated haemoglobin, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003-2017.

	Threshold	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Number needed to screen
<b>All participants</b>						
CoLaus/PsyCoLaus	13	65.5 (59.3 - 71.3)	77.6 (76.3 - 78.9)	15.6 (13.5 - 17.9)	97.3 (96.6 - 97.8)	26
Balkau	5	10.6 (7.1 - 15.0)	97.6 (97.0 - 98.0)	21.4 (14.6 - 29.6)	94.5 (93.8 - 95.2)	159
Kahn clinic	38	68.6 (62.5 - 74.3)	76.0 (74.6 - 77.3)	15.3 (13.2 - 17.5)	97.5 (96.8 - 98.0)	25
<b>Women (n=2904)</b>						
CoLaus/PsyCoLaus	13	72.1 (62.5 - 80.5)	80.0 (78.3 - 81.6)	14.0 (11.2 - 17.2)	98.5 (97.8 - 99.0)	32
Balkau	5	15.4 (9.1 - 23.8)	98.1 (97.4 - 98.6)	26.2 (15.8 - 39.1)	96.3 (95.4 - 97.0)	151
Kahn clinic	38	68.3 (58.4 - 77.1)	81.0 (79.4 - 82.6)	13.9 (11.1 - 17.3)	98.3 (97.6 - 98.8)	34
<b>Men (n=2373)</b>						
CoLaus/PsyCoLaus	13	60.9 (52.7 - 68.8)	74.4 (72.3 - 76.5)	17.2 (14.1 - 20.7)	95.6 (94.4 - 96.7)	20
Balkau	5	7.3 (3.7 - 12.7)	96.9 (96.0 - 97.7)	16.9 (8.8 - 28.3)	92.3 (91.0 - 93.5)	171
Kahn clinic	38	68.9 (60.8 - 76.2)	69.2 (67.0 - 71.4)	16.3 (13.5 - 19.4)	96.2 (95.0 - 97.2)	18

Results are expressed as value (95% confidence interval), except for the number needed to screen. Number needed to screen to detect one true incident case of diabetes mellitus: total number of participants screened/number of participants who developed T2DM and who scored positive.

## Supplemental information

S7 Table. Areas under the receiver operating characteristic (ROC) curves and incidence of diabetes per quintile of diabetes risk estimation score, women without history of gestational diabetes (n=2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003-2017

	AUC (95% CI)	P-value §	First	Second	Third	Fourth	Fifth
CoLaus/PsyCoLaus	0.804 (0.769 - 0.838)		0.8	3.3	4.7	9.1	21.4
Balkau	0.786 (0.751 - 0.820)	0.029	0.8	2.8	6.3	NA	16.6
Kahn clinic	0.805 (0.772 - 0.838)	0.903	0.4	1.6	2.5	6.3	15.3

Results are expressed as area under the curve and (95% confidence interval), and as percentage of participants developing diabetes during the 10.9 year follow-up. Diabetes was defined as fasting glucose level  $\geq 7$  mmol/L and/or presence of an oral antidiabetic or insulin treatment.

## Supplemental information

S8 Table. Diagnostic capacity of the different scores, women without history of gestational diabetes (n=2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003-2017.

	Threshold	Sensitivity	Specificity	Positive PV	Negative PV	N needed to screen
CoLaus/PsyCoLaus	13	65.8 (57.5 - 73.4)	79.7 (78.2 - 81.2)	14.8 (12.1 - 17.8)	97.8 (97.0 - 98.3)	30
Balkau	5	13.7 (8.6 - 20.4)	97.9 (97.3 - 98.4)	26.0 (16.6 - 37.2)	95.5 (94.7 - 96.2)	144
Kahn clinic	38	62.3 (53.9 - 70.2)	80.5 (79.0 - 82.0)	14.6 (11.9 - 17.7)	97.6 (96.8 - 98.2)	32

PV, predictive value; N, number. Results are expressed as value and (95% confidence interval). Number needed to screen to detect one true incident case of diabetes mellitus was computed as number of participants screened/number of participants who developed diabetes and who scored positive

## Supplemental information

**S9 Table. Characteristics of the four countries (France, Germany, Netherlands and UK) contributing data from the EPIC-Europe cohort study**

	Men	Women	All
Sample size	13,469 (21.9)	48,126 (78.1)	61,595
Age (years)	57.8 ± 8.2	56.2 ± 7.0	56.6 ± 7.3
Anthropometry			
Height (cm)	175 ± 7	162 ± 6	165 ± 8
Weight (kg)	80.3 ± 11.8	65.4 ± 11.6	68.7 ± 13.2
Body mass index (kg/cm <sup>2</sup> )	26.3 ± 3.4	24.8 ± 4.1	25.1 ± 4.0
Waist circumference (cm)	94.0 ± 9.9	79.6 ± 10.3	82.8 ± 11.8
Smoking status			
Never	3963 (29.4)	26763 (55.6)	30726 (49.9)
Former	6397 (47.5)	13927 (28.9)	20324 (33.0)
Current	3109 (23.1)	7436 (15.5)	10545 (17.1)
Hemodynamic			
Heart rate (bpm)	70 ± 12	72 ± 11	72 ± 11
Hypertension †	8629 (64.1)	24846 (51.6)	33475 (54.3)
Hypertension ‡	5805 (43.1)	16533 (34.4)	22338 (36.3)
Family history of diabetes			
All family members	1998 (14.8)	9041 (18.8)	11039 (17.9)
Father	685 (5.1)	3274 (6.8)	3959 (6.4)
Mother	1107 (8.2)	5281 (11.0)	6388 (10.4)
Physical inactivity	5917 (43.9)	22978 (47.7)	28895 (46.9)

BP, blood pressure; CVD, cardiovascular disease. † defined by SBP≥130 mm Hg or DBP ≥85 mm Hg or presence of antihypertensive drug treatment. ‡ defined by SBP≥140 mm Hg or DBP ≥90 mm Hg or presence of antihypertensive drug treatment. Results are expressed as mean ± standard deviation or as number of participants (%).

## Supplemental information

**S10 Table. Characteristics of the Tlalpan 2020 cohort, Mexico City, Mexico.**

	Men	Women	All
Sample size	405 (33.6)	798 (66.4)	1203
Age (years)	43.2 ± 4.6	43.3 ± 4.6	43.3 ± 4.6
Anthropometry			
Height (m)	170.1 ± 6.3	156.8 ± 6.2	161.3 ± 8.9
Weight (kg)	81.8 ± 13.7	67.9 ± 12.8	72.6 ± 14.7
Body mass index (kg/cm <sup>2</sup> )	28.2 ± 4.2	27.6 ± 4.8	27.8 ± 4.6
Waist circumference (cm)	97.7 ± 11.0	89.9 ± 11.6	92.5 ± 12.0
Hemodynamic			
Heart rate (bpm)	64 ± 8	65 ± 8	65 ± 8
Hypertension †	79 (19.5)	50 (6.3)	129 (10.7)
Hypertension ‡	26 (6.4)	15 (1.9)	41 (3.4)
Smoking status			
Never	210 (51.9)	420 (52.6)	630 (52.4)
Former	107 (26.4)	189 (23.7)	296 (24.6)
Current	88 (21.7)	189 (23.7)	277 (23.0)
Family history of diabetes			
All family members	155 (38.3)	377 (47.2)	532 (44.2)
Father	98 (24.2)	221 (27.7)	319 (26.5)
Mother	83 (20.5)	225 (28.2)	308 (25.6)
Physical inactivity	359 (88.6)	744 (93.2)	1,103 (91.7)

BP, blood pressure; CVD, cardiovascular disease. † defined by SBP ≥ 130 mm Hg or DBP ≥ 85 mm Hg or presence of antihypertensive drug treatment. ‡ defined by SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg or presence of antihypertensive drug treatment. Results are expressed as mean ± standard deviation or as number of participants (%).

## Supplemental information

**S11 Table. Characteristics of the Shahedieh cohort, Iran.**

	Men	Women	All
Sample size	5030 (50.4)	4945 (49.6)	9975 (100)
Age (years)	50.4±9.7	50.8±9.6	50.6±9.6
Anthropometry			
Height (cm)	170.5 ± 6.7	156.1 ± 6.0	163.4 ± 9.6
Weight (kg)	79.1 ± 13.9	72.4 ± 13.1	75.8 ± 13.9
Body mass index (kg/cm <sup>2</sup> )	27.2 ± 4.4	29.7 ± 5.1	28.4 ± 4.9
Waist circumference (cm)	94.7 ± 11.4	97.5 ± 12	96.1 ± 11.7
Hemodynamic			
Heart rate (bpm)	73 ± 9	74 ± 9	74 ± 9
Hypertension †	728 (14.7)	786 (16.1)	1514 (15.4)
Hypertension ‡	367 (7.4)	392 (8.0)	759 (7.7)
Smoking status			
Never	3952 (78.6)	4934 (99.8)	8886 (88.1)
Former	304 (6.0)	5 (0.1)	309 (3.1)
Current	774 (15.4)	6 (0.12)	780 (7.8)
Parental history of diabetes			
All family members	2550 (51.2)	2489 (50.9)	5039 (51.0)
Father	1021 (20.5)	1014 (20.7)	2035 (20.6)
Mother	665 (13.4)	670 (13.7)	1335 (13.5)
Physical inactivity*	4484 (90.0)	4383 (89.6)	8867 (89.8)

BP, blood pressure; CVD, cardiovascular disease. † defined by SBP≥130 mm Hg or DBP ≥85 mm Hg or presence of antihypertensive drug treatment. ‡ defined by SBP≥140 mm Hg or DBP ≥90 mm Hg or presence of antihypertensive drug treatment. Results are expressed as mean ± standard deviation or as number of participants (%). \*Less than 10% of day time moderate to high physical activity.

## Supplemental information

S12 Table. Performance of the new score and of two other clinically based scores, in original cohort (CoLaus/PsyCoLaus) and in the replication cohorts.

	AUC (95% CI)	p-value §	Goodness of fit †	AIC	BIC
CoLaus/PsyCoLaus					
CoLaus/PsyCoLaus	0.772 (0.750 - 0.794)		<0.001	2559.0	2572.1
Balkau	0.748 (0.726 - 0.770)	<0.001	0.009	2552.4	2565.5
Kahn clinic	0.774 (0.753 - 0.796)	0.668	0.032	2491.4	2504.5
European					
CoLaus/PsyCoLaus	0.788 (0.779 - 0.798)		<0.001	17419.3	17437.4
Balkau	0.793 (0.784 - 0.801)	0.091	<0.001	16855.6	16873.6
Kahn clinic	0.816 (0.807 - 0.825)	<0.001	0.036	16325.9	16343.9
Tlalpan 2020					
CoLaus/PsyCoLaus	0.791 (0.684 - 0.898)		0.716	214.2	224.4
Balkau	0.672 (0.561 - 0.782)	<0.001	0.221	236.3	246.5
Kahn clinic	0.778 (0.660 - 0.895)	0.575	0.025	216.5	226.7
Shahedieh					
CoLaus/PsyCoLaus	0.542 (0.459-0.626)		0.814	588.2	602.6
Balkau	0.564 (0.481-0.646)	0.476	0.358	587.5	601.9
Kahn clinic	0.513 (0.431-0.595)	0.300	0.702	589.7	604.1

§ comparing the model to the new one; † p-value for the Hosmer-Lemeshow test using 10 categories. AIC, Akaike's information criterion; BIC, Bayesian information criterion

## Supplemental information

S13 Table. Diagnostic capacity of the new score and of two other clinically based scores, in original cohort (CoLaus/PsyCoLaus) and in the replication cohorts.

	Threshold	Sensitivity	Specificity	Positive predictive value	Negative predictive value
CoLaus/PsyCoLaus					
CoLaus/PsyCoLaus	13	60.5 (55.5 - 65.3)	77.1 (75.8 - 78.2)	18.0 (16.0 - 20.1)	95.9 (95.2 - 96.5)
Balkau	5	10.1 (7.4 - 13.5)	97.4 (96.9 - 97.8)	24.4 (18.1 - 31.6)	92.9 (92.1 - 93.6)
Kahn clinic	38	64.0 (59.1 - 68.6)	74.6 (73.4 - 75.8)	17.3 (15.4 - 19.3)	96.1 (95.5 - 96.7)
European					
CoLaus/PsyCoLaus	13	59.3 (57.2 - 61.3)	82.7 (82.4 - 83.0)	11.7 (11.1 - 12.3)	98.1 (98.0 - 98.3)
Balkau	5	13.2 (11.9 - 14.7)	98.0 (97.9 - 98.1)	20.2 (18.2 - 22.3)	96.7 (96.6 - 96.8)
Kahn clinic	38	69.7 (67.7 - 71.5)	79.0 (78.6 - 79.3)	11.3 (10.8 - 11.9)	98.5 (98.4 - 98.6)
Tlalpan 2020					
CoLaus/PsyCoLaus	13	84.0 (83.9 - 95.5)	53.1 (50.2 - 56.0)	3.7 (2.3 - 5.6)	99.4 (98.4 - 99.8)
Balkau	5	8.0 (1.0 - 26.0)	99.4 (98.8 - 99.8)	22.2 (2.8 - 60.0)	98.1 (97.1 - 98.8)
Kahn clinic	38	76.0 (54.9 - 90.6)	61.3 (58.4 - 64.1)	4.0 (2.4 - 6.2)	99.2 (98.2 - 99.7)
Shahedieh					
CoLaus/PsyCoLaus	13	63.0 (47.5-76.8)	47.0 (46.0-48.0)	0.6 (0.4-0.8)	99.6 (99.4-99.8)
Balkau	5	0.0 (0.0-7.7)	98.3 (98.0-98.6)	0.0 (0.0-2.2)	99.5 (99.4-99.7)
Kahn clinic	38	50.0 (34.9-65.1)	52.7 (51.7-53.7)	0.5 (0.3-0.7)	99.6 (99.3-99.7)

Results are expressed as value and (95% confidence interval).

## Supplemental information

**S14 Table. Definitions of physical activity in the original and in the replication cohorts.**

<b>Cohort</b>	<b>Physical inactivity</b>	<b>Physical Activity</b>
CoLaus/PsyCoLaus	Less than twice 20 minutes leisure physical activity/week	≥twice 20 minutes leisure physical activity/week
European	Inactive and moderately inactive in the self-reported Cambridge physical activity index <sup>32</sup>	Active and moderately active in the self-reported Cambridge physical activity index <sup>32</sup>
Tlalpan 2020	Low IPAQ score <sup>33</sup>	Moderate or high IPAQ score <sup>33</sup>
Shahedieh	Moderate and severe physical activity < 10% of the day	Moderate and severe physical activity ≥10% of the day

## Supplemental information

**S15 Table. Diabetes prevalence in percentage of adults in 2014 classified by country and gender<sup>36</sup>**

	<b>Men</b>	<b>Women</b>
United Kingdom	6.6 (4.1-9.7)	4.9 (3.1-7.4)
France	7.5 (4.1-12.2)	4.4 (2.3-7.5)
Germany	6.0 (3.3-9.8)	3.9 (2.1-6.5)
Netherlands	5.2 (2.8-8.4)	3.5 (1.9-5.8)
Mexico	10.9 (5.8-17.7)	11.5 (6.4-18.3)
Iran	11.4 (7.2-17.2)	12.9 (8.4-18.8)

Results are expressed as percentage and (95% confidence interval).